About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis

By: Spotlight Growth

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of innovative therapies to treat nonalcoholic steatohepatitis (NASH), a liver disease with a significant unmet medical need. Shares of the biopharma company are skyrocketing 251% through late trading on Monday, December 19, 2022. Over the past three months, Madrigal Pharmaceuticals has seen average daily volume of 313,890 shares. However, volume of 7.17 million shares or dollar volume of around $1.56 billion, has already exchanged hands through late trading.

Shares of Madrigal Pharmaceuticals are surging after the company released positive topline results from its Phase 3 MAESTRO-NASH clinical trial of Resmetirom for the treatment of NASH and liver fibrosis. During the Phase 3 trial, the company conducted a 52-week serial liver biopsy study in over 950 patients. Resmetirom was found to achieve both primary and secondary endpoints with both its daily oral doses of 80 mg and 100 mg, relative to the placebo group.

The MAESTRO-NASH Phase 3 trial will continue to provide enrolled patients with therapy after the 52nd week of the clinical trial, for a total of 54 months to accrue hepatic clinical outcome events including histologic conversion to cirrhosis and hepatic decompensation events. At the beginning of the trial, baseline liver biopsy fibrosis scores were not good, with 84% NAS > 5 based on independent primary glass slide reads.

After 52 weeks of treatment, a second biopsy was conducted to assess efficacy of the treatment. The results showed a statistically significant response at both the 80 mg and 100 mg doses. Secondary liver biopsy endpoints were met at both doses after a >2 point reduction in NAS with no worsening fibrosis, >2 point reduction in NAS with ?1-stage improvement in fibrosis, NASH resolution (>2 point reduction in NAS) with >1-stage improvement in fibrosis, and a 2-stage reduction in fibrosis without worsening of NAS. Resmetirom was safe and well-tolerated throughout the study, similar to the results from the previous Phase 2 & 3 data.

Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal: “These pivotal Phase 3 results demonstrate the potential for resmetirom to help patients achieve improvement in both the underlying steatohepatitis that drives this disease and the resulting fibrosis that is associated with progression to cirrhosis and its complications. The topline data also reinforce our confidence in the safety and tolerability profile of resmetirom. We believe the Phase 3 MAESTRO clinical development program, including the MAESTRO-NAFLD-1 and MAESTRO-NAFLD-OLE safety clinical trials and the recently initiated MAESTRO-NASH-OUTCOMES clinical trial, provides a strong foundation for our new drug application (NDA) and the potential accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with liver fibrosis.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis appeared first on Spotlight Growth.

More News

View More
3 Auto Stocks to Watch as EV and Hybrid Demand Shifts
Via MarketBeat
Topics Economy Stocks World Trade
Tickers F GM TSLA
4 Stocks Set to Benefit From the PDT Rule Change
Via MarketBeat
Topics Regulatory Compliance
Tickers HOOD IBKR SCHW TSLA
154% Jump in Bullish Bets: Is Ford About to Hit the Gas?
Via MarketBeat
Topics Electric Vehicles World Trade
Tickers F
Chewy Stock: Why Analysts Say Boring May Be the Best Buy
Via MarketBeat
Topics Economy
Tickers BBY CHWY
Apple Stock Positioned for Holiday Gains With iPhone 17 Boost
Via MarketBeat
Topics Artificial Intelligence World Trade
Tickers AAPL MSFT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.